vs
CarParts.com, Inc.（PRTS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CarParts.com, Inc.的1.7倍（$207.3M vs $120.4M），CarParts.com, Inc.净利率更高（-9.6% vs -62.0%，领先52.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -9.8%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -14.9%）
GPC是一家总部位于美国佐治亚州亚特兰大的汽车与工业零部件分销商，1928年由弗雷泽兄弟创立，目前拥有约六万名员工。除美国本土市场外，公司业务还覆盖澳大拉西亚、比利时、加拿大、法国、德国、墨西哥、荷兰、波兰及英国，旗下拥有知名汽车零部件零售商NAPA Auto Parts和工业零部件分销商Motion。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PRTS vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.4M | $207.3M |
| 净利润 | $-11.6M | $-128.6M |
| 毛利率 | 33.2% | — |
| 营业利润率 | — | -54.7% |
| 净利率 | -9.6% | -62.0% |
| 营收同比 | -9.8% | 25.9% |
| 净利润同比 | 25.0% | 3.5% |
| 每股收益（稀释后） | $-0.82 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $120.4M | $207.3M | ||
| Q3 25 | $127.8M | $159.9M | ||
| Q2 25 | $151.9M | $166.5M | ||
| Q1 25 | $147.4M | $139.3M | ||
| Q4 24 | $133.5M | $164.6M | ||
| Q3 24 | $144.8M | $139.5M | ||
| Q2 24 | $144.3M | $147.0M | ||
| Q1 24 | $166.3M | $108.8M |
| Q4 25 | $-11.6M | $-128.6M | ||
| Q3 25 | $-10.9M | $-180.4M | ||
| Q2 25 | $-12.7M | $-115.0M | ||
| Q1 25 | $-15.3M | $-151.1M | ||
| Q4 24 | $-15.4M | $-133.2M | ||
| Q3 24 | $-10.0M | $-133.5M | ||
| Q2 24 | $-8.7M | $-131.6M | ||
| Q1 24 | $-6.5M | $-170.7M |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 33.1% | — | ||
| Q2 25 | 32.8% | — | ||
| Q1 25 | 32.1% | — | ||
| Q4 24 | 32.5% | — | ||
| Q3 24 | 35.2% | — | ||
| Q2 24 | 33.5% | — | ||
| Q1 24 | 32.4% | — |
| Q4 25 | — | -54.7% | ||
| Q3 25 | -7.9% | -106.9% | ||
| Q2 25 | -8.2% | -64.8% | ||
| Q1 25 | -10.3% | -102.6% | ||
| Q4 24 | -11.6% | -74.3% | ||
| Q3 24 | -6.9% | -94.6% | ||
| Q2 24 | -6.0% | -79.1% | ||
| Q1 24 | -3.9% | -151.9% |
| Q4 25 | -9.6% | -62.0% | ||
| Q3 25 | -8.5% | -112.8% | ||
| Q2 25 | -8.4% | -69.0% | ||
| Q1 25 | -10.4% | -108.5% | ||
| Q4 24 | -11.5% | -80.9% | ||
| Q3 24 | -6.9% | -95.7% | ||
| Q2 24 | -6.0% | -89.5% | ||
| Q1 24 | -3.9% | -156.8% |
| Q4 25 | $-0.82 | $-1.28 | ||
| Q3 25 | $-0.19 | $-1.81 | ||
| Q2 25 | $-0.23 | $-1.17 | ||
| Q1 25 | $-0.27 | $-1.57 | ||
| Q4 24 | $-0.28 | $-1.34 | ||
| Q3 24 | $-0.17 | $-1.40 | ||
| Q2 24 | $-0.15 | $-1.52 | ||
| Q1 24 | $-0.11 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $25.8M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $53.5M | $-80.0M |
| 总资产 | $184.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $25.8M | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $53.5M | $-80.0M | ||
| Q3 25 | $64.2M | $9.2M | ||
| Q2 25 | $62.4M | $151.3M | ||
| Q1 25 | $72.8M | $144.2M | ||
| Q4 24 | $85.2M | $255.0M | ||
| Q3 24 | $97.2M | $346.8M | ||
| Q2 24 | $103.9M | $432.4M | ||
| Q1 24 | $109.2M | $140.3M |
| Q4 25 | $184.9M | $1.5B | ||
| Q3 25 | $200.3M | $1.2B | ||
| Q2 25 | $189.6M | $1.3B | ||
| Q1 25 | $216.5M | $1.3B | ||
| Q4 24 | $210.6M | $1.5B | ||
| Q3 24 | $227.6M | $1.5B | ||
| Q2 24 | $238.0M | $1.6B | ||
| Q1 24 | $263.2M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-99.8M | ||
| Q3 25 | $-6.4M | $-91.4M | ||
| Q2 25 | $-25.6M | $-108.3M | ||
| Q1 25 | $5.5M | $-166.5M | ||
| Q4 24 | $1.8M | $-79.3M | ||
| Q3 24 | $8.5M | $-67.0M | ||
| Q2 24 | $-3.6M | $-77.0M | ||
| Q1 24 | $3.7M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $-8.3M | $-92.7M | ||
| Q2 25 | $-27.9M | $-110.7M | ||
| Q1 25 | $3.4M | $-167.8M | ||
| Q4 24 | $-631.0K | $-79.5M | ||
| Q3 24 | $4.9M | $-68.6M | ||
| Q2 24 | $-10.8M | $-79.0M | ||
| Q1 24 | $-3.8M | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | -6.5% | -58.0% | ||
| Q2 25 | -18.3% | -66.5% | ||
| Q1 25 | 2.3% | -120.5% | ||
| Q4 24 | -0.5% | -48.3% | ||
| Q3 24 | 3.4% | -49.2% | ||
| Q2 24 | -7.5% | -53.7% | ||
| Q1 24 | -2.3% | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 1.5% | 1.5% | ||
| Q1 25 | 1.4% | 1.0% | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 2.5% | 1.2% | ||
| Q2 24 | 4.9% | 1.4% | ||
| Q1 24 | 4.5% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRTS
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
